EUVIMEDEUVIMED entdecken
Open Access

Measurable Residual Disease Testing Following Nonintensive Chemoimmunotherapy is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study

Julie E Chang, Danielle McQuinn, Meredith Hyun, KyungMann Kim, Vaishalee P Kenkre, Saurabh A Rajguru, Priyanka A Pophali, Mariah Endres, Mitch Howard, Tim Wassenaar, Ruth Callaway Warren, Ryan J Mattison und 2 weitere

Clinical Lymphoma Myeloma and Leukemia · 2025

DOI: 10.1016/j.clml.2024.09.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Julie E Chang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI. Electronic address: jc2@medicine.wisc.edu. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Neoplasm, Residual, Antineoplastic Combined Chemotherapy Protocols, Immunotherapy. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Genentech Inc, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Obinutuzumab is hypothesized to improve progression-free survival (PFS) combined with bendamustine induction in mantle cell lymphoma (MCL). Measurable-residual disease (MRD) testing may predict benefit from maintenance therapy. METHODS: Adults (≥ 18 years) with untreated MCL ineligible for intensive therapies received 4 to 6 cycles of bendamustine + obinutuzumab (BO) followed by consolidation obinutuzumab (CO). Restaging after CO included MRD assessment by next-generation sequencing of bone marrow aspirate (BMA) and peripheral blood (PB). Maintenance obinutuzumab (MO) was omitted for patients with imaging complete response (CR) and MRD-negativity in PB/BMA. All other patients received 8 cycles MO. Primary endpoint is PFS; secondary endpoints are response rates, overall survival, and estimation of MRD status. RESULTS: Twenty-one patients enrolled, with median age 70 years and stage IV disease in 95%. Twenty patients completed BO; 10 patients received MO per protocol. Six patients did not complete MO due to progression (n = 4), infection (n = 1) and carcinoma (n = 1). Overall response is 95% (75% CR, 20% partial response). Concordance rate between post-consolidation MRD testing in PB and BMA was 70%. After a median follow-up of 43.9 months, median PFS is 46.5 months. The observed difference between 2-year PFS in groups receiving MO versus observation was not statistically significant (HR 0.45, 95% CI, 0.10-1.91). Most common grade 3/4 toxicities were neutropenia, leukopenia, and infections. CONCLUSIONS: BO is a tolerable induction regimen with higher rates of CR compared with historical rates with bendamustine + rituximab. Omission of MO did not worsen outcomes in patients achieving MRD-negative status after nonintensive induction/consolidation therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Mantle-CellNeoplasm, ResidualAntineoplastic Combined Chemotherapy ProtocolsImmunotherapyHumansAgedFemaleMaleMiddle AgedAged, 80 and overBendamustine HydrochlorideMaintenance ChemotherapyAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

BendamustineMantle cell lymphomaMeasurable residual diseaseMinimal residual diseaseNext-generation sequencingObinutuzumab

Substanzen

Bendamustine HydrochlorideobinutuzumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI. Electronic address: jc2@medicine.wisc.edu.
  • Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI.
  • Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI.
  • Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI; Department of Medicine, University of Wisconsin Carbone Cancer Center, Madison, WI.
  • Department of Medicine, University of Wisconsin Carbone Cancer Center, Madison, WI.
  • Department of Medicine, ProHealth Care, Waukesha, WI.

Förderung

  • NCI NIH HHS
  • Genentech Inc
  • National Institutes of Health
  • Adaptive Biotechnologies
  • National Cancer Institute

Zitieren

APA

Chang, J. E., McQuinn, D., Hyun, M., Kim, K., Kenkre, V. P., Rajguru, S. A., Pophali, P. A., Endres, M., Howard, M., Wassenaar, T., Warren, R. C., Mattison, R. J., Wisinski, K. B., & Fletcher, C. D. (2025). Measurable Residual Disease Testing Following Nonintensive Chemoimmunotherapy is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.09.014

Vancouver

Chang JE, McQuinn D, Hyun M, Kim K, Kenkre VP, Rajguru SA, et al. Measurable Residual Disease Testing Following Nonintensive Chemoimmunotherapy is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2024.09.014

BibTeX
@article{Chang2025,
  author = {Chang, Julie E and McQuinn, Danielle and Hyun, Meredith and Kim, KyungMann and Kenkre, Vaishalee P and Rajguru, Saurabh A and Pophali, Priyanka A and Endres, Mariah and Howard, Mitch and Wassenaar, Tim and Warren, Ruth Callaway and Mattison, Ryan J and Wisinski, Kari B and Fletcher, Christopher D},
  title = {Measurable Residual Disease Testing Following Nonintensive Chemoimmunotherapy is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  doi = {10.1016/j.clml.2024.09.014}
}
Kostenlos starten →